Updated:
Locemia Partners
Locemia Partners maintains two advisory offices in Boston and San Francisco, United States.
Locemia Partners
Locemia Partners maintains two advisory offices in Boston and San Francisco, United States. The firm's founding year and wealth origin are not publicly disclosed, and no named principals or operators appear in available records. The family office structure suggests a low-publicity posture typical of single-family offices that do not market to outside allocators. The firm pursues minority growth equity investments, primarily in healthcare and technology sectors. Its known portfolio includes Locemia Solutions, a Montreal-based developer of a needle-free glucagon nasal powder for severe hypoglycemia rescue (per Locemia Solutions website). The geographic focus spans North America, with a concentration in the US and Canada. The firm does not disclose deal-level co-investors or fund commitments. Total assets under management are undisclosed, and no team size or additional offices beyond Boston and San Francisco are documented. The firm has no known philanthropic vehicles, operating companies, or club memberships in public records. No dated operational events from the last 24 months are verifiable. The structural differentiator is the firm's link to Locemia Solutions as a portfolio company, indicating a willingness to fund clinical-stage medical device companies addressing niche metabolic conditions. This suggests a hands-on approach to high-risk healthcare investments, though broader strategy details remain opaque.
General information
Firm type
Family Office
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Boston
Corporate office
Boston, MA, United States
Additional offices
San Francisco, CA, United States
Sector focus
Frequently asked questions
Who manages investment decisions at Locemia Partners?
The firm does not publicly name any investment professionals, principals, or CIOs. No team members are listed on the Locemia Partners website or in any external biographies. The investment decision-making structure is not disclosed.
What is the investment focus of Locemia Partners?
Locemia Partners targets minority growth equity investments in healthcare and technology companies across North America. Its known portfolio company, Locemia Solutions, is a Montreal-based medical device firm developing a needle-free glucagon nasal powder for severe hypoglycemia (per Locemia Solutions website).
Does Locemia Partners invest in funds or only direct deals?
The firm does not disclose its allocation between fund commitments and direct investments. Available public records indicate a focus on direct minority growth equity stakes, but no fund-of-funds or co-investment vehicles are confirmed.
What is the relationship between Locemia Partners and Locemia Solutions?
Locemia Partners appears to be an investor in Locemia Solutions, a separate company focused on developing a needle-free glucagon rescue treatment. Locemia Solutions is headquartered in Montreal, Canada, and its team has experience in diabetes management and drug delivery (per Locemia Solutions website).
Where does the wealth behind Locemia Partners originate?
The wealth origin for Locemia Partners is not publicly disclosed. No information links the family office to any specific industry or fortune.
What is the firm's geographic investment footprint?
Locemia Partners invests in North America, with a concentration in the United States and Canada. Its advisory offices are located in Boston and San Francisco, and portfolio company Locemia Solutions is based in Montreal.
Does Locemia Partners have a public track record of exits or returns?
No exits, returns, or realized investments by Locemia Partners are publicly documented. The firm does not communicate performance data.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: